216 related articles for article (PubMed ID: 11479150)
21. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
[TBL] [Abstract][Full Text] [Related]
23. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.
Chan TM; Tse KC; Tang CS; Lai KN; Li FK
Lupus; 2005; 14(4):265-72. PubMed ID: 15864912
[TBL] [Abstract][Full Text] [Related]
25. Longterm followup of childhood lupus nephritis.
Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
[TBL] [Abstract][Full Text] [Related]
26. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
Austin HA; Klippel JH; Balow JE; le Riche NG; Steinberg AD; Plotz PH; Decker JL
N Engl J Med; 1986 Mar; 314(10):614-9. PubMed ID: 3511372
[TBL] [Abstract][Full Text] [Related]
27. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
[TBL] [Abstract][Full Text] [Related]
28. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F; Ayili D; Sahiner S
J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
[TBL] [Abstract][Full Text] [Related]
31. [Effect of methylprednisolone pulse therapy in patients with lupus nephritis assessed by WHO morphologic classification].
Makino H; Yamasaki Y; Hayashi Y; Haramoto T; Shikata K; Kumagai I; Taniai K; Takahashi K; Ota Z
Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):791-9. PubMed ID: 2273595
[TBL] [Abstract][Full Text] [Related]
32. [Laboratory and morphologic parameters in patients with lupus nephritis].
Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive therapy in lupus nephritis.
D'Cruz D; Cuadrado MJ; Mujic F; Tungekar MF; Taub N; Lloyd M; Khamashta MA; Hughes GR
Clin Exp Rheumatol; 1997; 15(3):275-82. PubMed ID: 9177922
[TBL] [Abstract][Full Text] [Related]
34. Pulse cyclophosphamide induction treatment in Thai children with diffuse proliferative lupus nephritis.
Opastirakul S; Chartapisak W
Nephrology (Carlton); 2012 Mar; 17(3):269-73. PubMed ID: 22181066
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
[TBL] [Abstract][Full Text] [Related]
36. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
Frutos MA; Martín Gómez A; de Ramón E; Camps MT; Valera A; García I; Fernández Nebro A
Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
[TBL] [Abstract][Full Text] [Related]
37. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
Shen K; Yu Y; Tang Z; Liu Z; Li L
Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
[TBL] [Abstract][Full Text] [Related]
38. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
40. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
